Effects of rosuvastatin on postprandial leukocytes in mildly hyperlipidemic patients with premature coronary sclerosis.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsOostrom, A J H H M van
Plokker, H W M
Asbeck, B S van
Rabelink, T J
Kessel, K P M van
Jansen, E H J M
Stehouwer, C D A
Cabezas, M Castro
MetadataShow full item record
TitleEffects of rosuvastatin on postprandial leukocytes in mildly hyperlipidemic patients with premature coronary sclerosis.
PubliekssamenvattingWe investigated whether pro-inflammatory aspects of the postprandial phase can be modulated by rosuvastatin in premature coronary artery disease (CAD) patients. Herefore standardized 8 h oral fat loading tests were performed off-treatment and after rosuvastatin 40 mg/d in 20 male CAD patients (50 +/- 4 years). The expression of leukocyte activation markers CD11a, CD11b, CD62L and CD66b was studied using flowcytometry. Migration of isolated neutrophils towards chemoattractants was determined in a fluorescence-based assay. Rosuvastatin did not affect baseline leukocyte counts nor the postprandial neutrophil increment (maximum mean increase +10% pre- and +14% post-treatment, P < 0.01 for each). Rosuvastatin reduced baseline platelets (from 266 +/- 78 to 225 +/- 74 x 10(9) cells/L, P < 0.001) and blunted the postprandial platelet count change (maximum mean increase +6%, P = 0.01, and 0%, respectively). The baseline expression of CD11a, CD11b and CD62L increased on most types of leukocytes by rosuvastatin, whereas the postprandial responses were unaffected. Pretreatment, postprandial neutrophil migration increased dose-dependently, but there were no postprandial changes after rosuvastatin. The latter effect was unrelated to changes in lipoprotein concentrations. In conclusion, in CAD patients postprandial pro-inflammatory and pro-coagulant changes can be modified by rosuvastatin. These apparently lipid-lowering independent effects may render protection against atherosclerosis.
- Leukocyte activation by triglyceride-rich lipoproteins.
- Authors: Alipour A, van Oostrom AJ, Izraeljan A, Verseyden C, Collins JM, Frayn KN, Plokker TW, Elte JW, Castro Cabezas M
- Issue date: 2008 Apr
- In vivo evidence for chylomicrons as mediators of postprandial inflammation.
- Authors: de Vries MA, Klop B, Alipour A, van de Geijn GJ, Prinzen L, Liem AH, Valdivielso P, Rioja Villodres J, Ramírez-Bollero J, Castro Cabezas M
- Issue date: 2015 Dec
- Comparison of different methods to investigate postprandial lipaemia.
- Authors: van Oostrom AJ, Alipour A, Sijmonsma TP, Verseyden C, Dallinga-Thie GM, Plokker HW, Castro Cabezas M
- Issue date: 2009 Jan
- Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia.
- Authors: Kostapanos MS, Derdemezis CS, Filippatos TD, Milionis HJ, Kiortsis DN, Tselepis AD, Elisaf MS
- Issue date: 2008 Jan 14
- Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients.
- Authors: Antonopoulos S, Mikros S, Mylonopoulou M, Kokkoris S, Giannoulis G
- Issue date: 2006 Jan